ACCESS TO DUODOPA FOR PEOPLE WITH PARKINSON'S DISEASE

Motion Text

That this House believes that people with Parkinson's disease should always have the full range of treatment options open to them; notes with concern that in England people with Parkinson's disease are currently unable to access Duodopa; recognises that Duodopa is a licensed and often life-changing treatment that can give people back their independence when all other treatment options have been exhausted; further recognises that, when people cannot access Duodopa, their health and care needs significantly increase, with significant cost implications; further recognises that the Clinical Priorities Advisory Group review of Duodopa has been characterised by delays and a lack of transparency; and calls on NHS England urgently to review the availability of Duodopa and take action to ensure that people are able to access the treatment.